Cover Image
市場調查報告書

美國的眼科手術系統市場

U.S. Ophthalmic Surgical Systems Market

出版商 Medtech Insight 商品編碼 298989
出版日期 內容資訊 英文 84 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
美國的眼科手術系統市場 U.S. Ophthalmic Surgical Systems Market
出版日期: 2014年04月01日 內容資訊: 英文 84 Pages
簡介

美國受到嚴重眼科疾病的影響人數為3500萬多。由於人口高齡化及糖尿病造成的失明等理由,該患者數今後預測將大幅擴大。此外,由於雷射和水晶體超音波乳化吸引等微創能量利用技術的開發,實現了安全兼有效的視力回復治療法。在這樣的推進背景下,美國眼科手術系統市場將由2013年市場交易價16億9580萬美金大幅擴張,到2018年推定將達到22億5640萬美金的規模。

本報告以這樣的美國的眼科手術系統市場為焦點,驗証並預測上述期間規模的轉變,再彙整不同疾病的最新療法,參與企業等分析資訊,為您概述為以下內容。

摘要整理

  • 臨床性概要
  • 老年性黃斑部病變(AMD)
  • 白內障
  • 糖尿病視網膜病變(DR)
  • 青光眼
  • 屈光異常
  • 市場
  • 調查方法

第1章 眼科手術系統市場

  • 臨床性概要
    • 老年性黃斑部病變
    • 白內障
    • 糖尿病視網膜病變
    • 青光眼
    • 屈光異常
  • 眼科治療
    • 老年性黃斑部病變
      • 抗血管新生療法
      • 光動力療法
      • 經瞳孔熱療法(TTT)
      • 全視網膜雷射
    • 白內障手術
      • 囊解剖
      • 手術數量預測
    • 糖尿病視網膜病變
      • 糖尿病視網膜病變雷射手術
      • 手術數量預測
    • 青光眼雷射小樑網整形術
      • 手術數量預測
    • 屈光異常矯正術
      • 雷射利用的視力矯正
      • 雷射屈光矯正角膜切除術(PRK)
      • 準分子雷射層狀角膜塑型術(LASIK)
      • 雷射角膜表皮形成術(LASEK)
      • PAI雷射屈光角膜層狀重塑術(PAI-LASIK)
      • 手術數量預測
  • 市場分析
    • 市場預測
  • 競爭分析
    • 市場佔有率

第2章 企業簡介(簡歷,組織,產業收購,手術系統,業績,財務等)

  • Abbott Laboratories
  • Carl Zeiss Meditec AG
  • IRIDEX Corporation
  • Lumenis Ltd.
  • Novartis
  • Valeant Pharmaceuticals

附錄:企業一覽

目錄
Product Code: A560

In the United States (U.S.), serious ophthalmic disease affects more than 35 million. This number is expected to significantly increase due to the aging of the population and disorders such as diabetes that may result in progressive vision loss. Alarmingly, the number of patients with cataracts is expected to increase significantly over the next decade, contributing a substantial increase in the number of cataract surgeries.

The development of new, minimally invasive energy-based (laser/phacoemulsification or “phaco”) technologies is providing safe and effective, medically necessary, vision-saving treatment to millions of patients, particularly those with cataracts who also seek vision correction surgery. Meanwhile, non-medically necessary, high-cost refractive surgery, such as laser in situ keratomileusis (LASIK) vision correction, continues to increase despite several setbacks.

Overall, more than an estimated 5.5 million directed-energy based (laser/phaco) ophthalmic procedures, including cataract laser surgery, diabetic retinopathy laser surgery, glaucoma/laser trabeculoplasty and laser-based vision correction surgery, were estimated to have been performed in the U.S. in 2013. The advancement of safer and more cost-effective laser-based technologies, such as femtosecond laser cataract surgery and other technological improvements, are expected to improve patient outcomes and drive ophthalmic surgical procedures and market growth over the next half-decade.

For the purposes of this report, the U.S. market for ophthalmic surgical systems includes sales derived from laser and phaco systems for vision correction and the minimally invasive treatment of cataracts, glaucoma, retinal, and other ophthalmic disorders. In addition to ophthalmic surgical systems sales, the market forecast includes revenues derived from surgical accessories/instruments and disposables utilized in minimally invasive directed energy-based ophthalmic surgery. In 2013, the U.S. ophthalmic surgical systems market was valued at approximately $1,695.8 million. Over the forecast period covered by this report, total sales in this market are expected to increase at a compound annual rate of 5.9%, reaching an estimated $2,256.4 million in the year 2018.

This dynamic, new report from Medtech Insight includes analyses of products, current/forecast markets, competitors, and opportunities in the U.S. ophthalmic surgical systems market. Covered topics in this report include an overview of common ophthalmic diseases/disorders and therapies; U.S. procedure volumes; laser/phaco/energy-based surgical systems, next-generation laser-based systems and emerging technologies; and company profiles.

Table of Contents

EXECUTIVE SUMMARY

  • i. Clinical Overview
  • a. Age-Related Macular Degeneration
  • b. Cataracts
  • c. Diabetic Retinopathy
  • d. Glaucoma
  • e. Refractive Errors
  • ii. Market
  • iii. Methodology

1. U.S. OPHTHALMIC SURGICAL SYSTEMS MARKET

  • 1.1. Clinical Overview
    • 1.1.1. Age-Related Macular Degeneration
    • 1.1.2. Cataracts
    • 1.1.3. Diabetic Retinopathy
    • 1.1.4. Glaucoma
    • 1.1.5. Refractive Errors
  • 1.2. Ophthalmic Procedures
    • 1.2.1. Age-Related Macular Degeneration
      • 1.2.2.1. Anti-Angiogenic Therapy
      • 1.2.2.2. Verteporfin Photodynamic Therapy
      • 1.2.2.3. Transpupillary Thermotherapy
      • 1.2.2.4. Retinal Photocoagulation
    • 1.2.2. Cataract Surgery
      • 1.2.1.1. Capsulotomy
      • 1.2.1.2. Procedure Volumes Forecast
    • 1.2.3. Diabetic Retinopathy Laser Surgery
      • 1.2.3.1. Procedure Volumes Forecast
    • 1.2.4. Glaucoma-Laser Trabeculoplasty
      • 1.2.4.1. Procedure Volumes Forecast
    • 1.2.5. Refractive Surgery
      • 1.2.5.1. Laser-Based Vision Correction
      • 1.2.5.2. Photorefractive Keratectomy
      • 1.2.5.3. Laser In Situ Keratomileusis
      • 1.2.5.4. Laser Epithelial Keratomileusis
      • 1.2.5.6. Photoablative Inlay Laser In Situ Keratomileusis
      • 1.2.5.7. Procedure Volumes Forecast
  • 1.3. Market Analysis
    • 1.3.1. Market Forecast
  • 1.4. Competitive Analysis
    • 1.4.1. Market Share
  • Exhibit 1-1: 2013, Estimated U.S. Prevalence of Selected Ophthalmic Conditions
  • Exhibit 1-2: Laser Therapy for Age-Related Macular Degeneration, U.S. Procedure Volumes Forecast, 2011-2018
  • Exhibit 1-3: Cataract Surgery, U.S. Procedure Volumes Forecast, 2011-2018 (in Thousands)
  • Exhibit 1-4: Diabetic Retinopathy Laser Surgery, U.S. Procedure Volumes Forecast, 2011-2018 (in Thousands)
  • Exhibit 1-5: Glaucoma Surgery, U.S. Procedure Volumes Forecast, 2011-2018 (in Thousands)
  • Exhibit 1-6: Refractive Laser Surgery, U.S. Procedure Volumes Forecast, 2011-2018 (in Thousands)
  • Exhibit 1-7: Selected Market Drivers and Limiters
  • Exhibit 1-8: U.S. Ophthalmic Surgical Systems, Market Forecast, 2013-2018
  • Exhibit 1-9: 2013, U.S. Ophthalmic Surgical Systems Market, Estimated Percentage of Sales, by Application
  • Exhibit 1-10: 2013, Leading Competitors in the U.S. Ophthalmic Surgical Systems Market and Applications for Leading Products
  • Exhibit 1-11: 2013, U.S. Ophthalmic Surgical Systems Market, Share by Supplier

2. COMPANY PROFILES

  • 2.1. Abbott Laboratories
    • 2.1.1. Background
    • 2.1.2. Abbott Medical Optics Division
    • 2.1.3. Acquisitions
    • 2.1.4. Surgical Systems
    • 2.1.5. Medical Optics Revenues
    • 2.1.6. Selected Financials
  • 2.2. Carl Zeiss Meditec AG
    • 2.2.1. Background
    • 2.2.2. Carl Zeiss Ophthalmology Business
    • 2.2.3. Acquisitions
    • 2.2.4. Surgical Systems
    • 2.2.5. Ophthalmology Segment Revenues
    • 2.2.6. Selected Financials
  • 2.3. IRIDEX Corporation
    • 2.3.1. Background
    • 2.3.2. Acquisitions/Divestitures
    • 2.3.3. Surgical Systems
    • 2.3.4. Selected Financials
  • 2.4. Lumenis Ltd.
    • 2.4.1. Background
    • 2.4.2. Ophthalmic Division
    • 2.4.3. Surgical Systems
    • 2.4.4. Ophthalmic Division Revenues
    • 2.4.5. Selected Financials
  • 2.5. Novartis
    • 2.5.1. Background
    • 2.5.2. Alcon Division
    • 2.5.3. Acquisitions
    • 2.5.4. Surgical Systems
    • 2.5.5. Alcon Division Revenues
    • 2.5.6. Selected Financials
  • 2.6. Valeant Pharmaceuticals
    • 2.6.1. Background
    • 2.6.2. Bausch and Lomb
    • 2.6.3. Acquisitions
    • 2.6.4. Surgical Systems
    • 2.6.5. Bausch + Lomb Revenues
    • 2.6.6. Selected Financials
Back to Top